Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 19 | 2025 | 967 | 1.500 |
Why?
|
| Vietnam | 24 | 2025 | 173 | 0.940 |
Why?
|
| Methadone | 8 | 2017 | 134 | 0.840 |
Why?
|
| Opiate Substitution Treatment | 8 | 2017 | 205 | 0.760 |
Why?
|
| Substance Abuse, Intravenous | 4 | 2025 | 80 | 0.680 |
Why?
|
| Sex Workers | 2 | 2025 | 17 | 0.640 |
Why?
|
| AIDS Serodiagnosis | 2 | 2016 | 19 | 0.540 |
Why?
|
| Drug Users | 4 | 2016 | 30 | 0.490 |
Why?
|
| Homosexuality, Male | 4 | 2025 | 38 | 0.490 |
Why?
|
| Unsafe Sex | 3 | 2016 | 27 | 0.480 |
Why?
|
| Anti-HIV Agents | 5 | 2025 | 154 | 0.460 |
Why?
|
| Ketocholesterols | 1 | 2014 | 1 | 0.450 |
Why?
|
| Amyloid | 1 | 2014 | 69 | 0.430 |
Why?
|
| HIV Seropositivity | 4 | 2017 | 84 | 0.390 |
Why?
|
| Peptide Fragments | 1 | 2014 | 410 | 0.380 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 297 | 0.380 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2022 | 24 | 0.360 |
Why?
|
| Cross-Sectional Studies | 16 | 2022 | 2569 | 0.350 |
Why?
|
| Attitude to Health | 1 | 2013 | 289 | 0.350 |
Why?
|
| Transgender Persons | 2 | 2022 | 69 | 0.340 |
Why?
|
| Tobacco Use Disorder | 3 | 2017 | 246 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 759 | 0.290 |
Why?
|
| Opioid-Related Disorders | 5 | 2017 | 506 | 0.270 |
Why?
|
| Smoking | 3 | 2017 | 865 | 0.260 |
Why?
|
| Socioeconomic Factors | 6 | 2017 | 777 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 2 | 2025 | 105 | 0.260 |
Why?
|
| Alcoholism | 3 | 2024 | 318 | 0.240 |
Why?
|
| Adult | 20 | 2025 | 16782 | 0.240 |
Why?
|
| Risk-Taking | 5 | 2016 | 162 | 0.240 |
Why?
|
| Qualitative Research | 3 | 2024 | 683 | 0.230 |
Why?
|
| Condoms | 2 | 2016 | 48 | 0.230 |
Why?
|
| Needle Sharing | 1 | 2015 | 15 | 0.230 |
Why?
|
| Sentinel Surveillance | 1 | 2025 | 19 | 0.230 |
Why?
|
| Social Class | 4 | 2017 | 133 | 0.220 |
Why?
|
| Drug Resistance, Viral | 1 | 2025 | 157 | 0.210 |
Why?
|
| Sexual Behavior | 2 | 2016 | 194 | 0.200 |
Why?
|
| Substance-Related Disorders | 5 | 2017 | 732 | 0.200 |
Why?
|
| Female | 22 | 2025 | 32785 | 0.200 |
Why?
|
| Analgesics, Opioid | 3 | 2017 | 536 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 479 | 0.200 |
Why?
|
| Motivation | 2 | 2015 | 285 | 0.200 |
Why?
|
| Male | 21 | 2025 | 29818 | 0.190 |
Why?
|
| HIV-1 | 2 | 2025 | 721 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 563 | 0.170 |
Why?
|
| Harm Reduction | 2 | 2015 | 33 | 0.170 |
Why?
|
| Health Personnel | 1 | 2024 | 367 | 0.170 |
Why?
|
| Young Adult | 8 | 2025 | 4682 | 0.170 |
Why?
|
| Humans | 25 | 2025 | 63282 | 0.160 |
Why?
|
| Smoking Cessation | 2 | 2015 | 550 | 0.160 |
Why?
|
| Adolescent | 8 | 2025 | 6238 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 94 | 0.160 |
Why?
|
| Sexual and Gender Minorities | 1 | 2021 | 76 | 0.160 |
Why?
|
| Counseling | 2 | 2025 | 362 | 0.150 |
Why?
|
| Narcotics | 2 | 2016 | 58 | 0.150 |
Why?
|
| Deductibles and Coinsurance | 1 | 2017 | 9 | 0.140 |
Why?
|
| Prevalence | 5 | 2016 | 1378 | 0.130 |
Why?
|
| Mutation | 1 | 2025 | 2607 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 137 | 0.120 |
Why?
|
| Educational Status | 2 | 2016 | 275 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2016 | 42 | 0.120 |
Why?
|
| Drug Costs | 1 | 2016 | 56 | 0.120 |
Why?
|
| Social Stigma | 1 | 2016 | 73 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 76 | 0.120 |
Why?
|
| Membrane Fluidity | 1 | 2014 | 15 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2016 | 122 | 0.110 |
Why?
|
| Jurkat Cells | 1 | 2014 | 110 | 0.110 |
Why?
|
| Quality of Life | 3 | 2016 | 1226 | 0.110 |
Why?
|
| Membrane Microdomains | 1 | 2014 | 49 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 210 | 0.110 |
Why?
|
| Liposomes | 1 | 2014 | 107 | 0.110 |
Why?
|
| Voluntary Programs | 1 | 2013 | 4 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 435 | 0.100 |
Why?
|
| Cholesterol | 1 | 2014 | 259 | 0.100 |
Why?
|
| Protein Transport | 1 | 2014 | 401 | 0.100 |
Why?
|
| Urethral Diseases | 1 | 2012 | 13 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 358 | 0.100 |
Why?
|
| Syphilis | 1 | 2012 | 25 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 433 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2012 | 75 | 0.090 |
Why?
|
| Middle Aged | 7 | 2025 | 17550 | 0.090 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 2674 | 0.090 |
Why?
|
| Gonorrhea | 1 | 2012 | 157 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 314 | 0.070 |
Why?
|
| Models, Organizational | 2 | 2016 | 93 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2016 | 286 | 0.060 |
Why?
|
| Law Enforcement | 1 | 2015 | 26 | 0.060 |
Why?
|
| Injections | 1 | 2024 | 81 | 0.060 |
Why?
|
| Workload | 1 | 2025 | 125 | 0.060 |
Why?
|
| Self Report | 2 | 2017 | 375 | 0.060 |
Why?
|
| Medication Adherence | 2 | 2016 | 202 | 0.060 |
Why?
|
| Organizational Culture | 1 | 2025 | 110 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 114 | 0.050 |
Why?
|
| Viral Load | 1 | 2025 | 231 | 0.050 |
Why?
|
| Leadership | 1 | 2025 | 206 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2015 | 509 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 60 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 738 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 595 | 0.040 |
Why?
|
| Financing, Personal | 1 | 2017 | 23 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 94 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 690 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 90 | 0.030 |
Why?
|
| Health Services Administration | 1 | 2016 | 4 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 96 | 0.030 |
Why?
|
| Binge Drinking | 1 | 2016 | 37 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 94 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 377 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 935 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 193 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 5343 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 202 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 121 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1274 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 296 | 0.020 |
Why?
|
| Social Support | 1 | 2015 | 371 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1122 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 434 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 892 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5656 | 0.010 |
Why?
|